The Food and Drug Administration today released draft guidance for assessing risk evaluation and mitigation strategies. FDA may require a REMS before approving certain drugs, including biologics, to help ensure its benefits outweigh its risks. FDA Commissioner Scott Gottlieb, M.D., said the guidance provides a framework for companies to develop an assessment plan when they develop a REMS program to improve the quality of the information used to assess the program’s effectiveness and provide post-market evidence that the REMS is meeting its risk mitigation goals. “We need to make sure that the REMS are achieving their public health goals, and that we’re designing and implementing these approaches in ways that minimize burdens to patients and providers,” he said.

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response yesterday released resources focused on…
Headline
The Federal Emergency Management Agency this month issued COVID-19 pandemic operational guidance for the forthcoming hurricane season. Included in the document…
Headline
The Committee on Ways and Means today convened a hearing examining the disproportionate effect COVID-19 is having on minority communities. “Many communities…
Perspective
In Michigan, African Americans make up 14% of the population … but account for 40% of the COVID-19 deaths. In Chicago: 30% of the population … and 46% of the…
Headline
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related…
Headline
Hospitals and health systems continue to provide care for our most vulnerable communities by addressing social needs, educating on COVID-19 risks and…